The Presence and Severity of Chronic Kidney Disease Predicts All-Cause Mortality in Type 1 Diabetes
Open accessThe DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
OBJECTIVES: This study aimed to identify clinical features associated with premature mortality in a large contemporary cohort of adults with type 1 diabetes. RESEARCH DESIGN AND METHODS: The Finnish Diabetic Nephropathy (FinnDiane) study is a national multicenter prospective follow-up study of 4,201 adults with type 1 diabetes from 21 university and central hospitals, 33 district hospitals, and 26 primary health care centers across Finland. RESULTS: During a median 7 years of follow-up, there were 291 deaths (7%), 3.6-fold (95% CI 3.2–4.0) more than that observed in the age- and sex-matched general population. Excess mortality was only observed in individuals with chronic kidney disease. Individuals with normoalbuminuria showed no excess mortality beyond the general population (standardized mortality ratio [SMR] 0.8, 95% CI 0.5–1.1), independent of the duration of diabetes. The presence of microalbuminuria, macroalbuminuria, and end-stage kidney disease was associated with 2.8, 9.2, and 18.3 times higher SMR, respectively. The increase in mortality across each stage of albuminuria was equivalent to the risk conferred by preexisting macrovascular disease. In addition, the glomerular filtration rate was independently associated with mortality, such that individuals with impaired kidney function, as well as those demonstrating hyperfiltration, had an increased risk of death. CONCLUSIONS: An independent graded association was observed between the presence and severity of kidney disease and mortality in a large contemporary cohort of individuals with type 1 diabetes. These findings highlight the clinical and public health importance of chronic kidney disease and its prevention in the management of type 1 diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Diabetic nephropathy, whether manifesting as microalbuminuria, macroalbuminuria, or a reduced glomerular filtration rate progressively augments the overall risk of macrovascular complications.118”
From Type 1 diabetes (2018) · cites this paper as [118]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, UACR is a continuous measurement, and differences within the normal and abnormal ranges are associated with kidney and cardiovascular outcomes (6,10,11).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, UACR is a continuous measurement, and differences within the normal and abnormal ranges are associated with kidney and cardiovascular outcomes (6,11,12).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [12]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Toprak, O., Kurt, H., Sarı, Y., Şarkış, C., Us, H., & Kırık, A. (2017) · Kidney and Blood Pressure Research · doi:10.1159/000468530 · Cited by 29,627
Levey, A. S., Coresh, J., Bolton, K., Culleton, B. F., Harvey, K. S., Ikizler, T. A., Johnson, C. A., Kausz, A., Kimmel, P. L., Kusek, J. W., et al. (2002) · University of Groningen research database (University of Groningen / Centre for Information Technology) · Cited by 11,633
Proportional hazards tests and diagnostics based on weighted residuals
GRAMBSCH, P. M., & THERNEAU, T. M. (1994) · Biometrika · doi:10.1093/biomet/81.3.515 · Cited by 5,885 · cited 3×
“9* Any retinopathy 76 (29)† 1,313 (50) 420 (93)† 290 (99)† Retinopathy requiring laser therapy 27 (10)† 683 (25) 360 (78)† 288 (97)† Current smoker 98 (37)† 614 (24) 95 (22) 49 (16)† Established macrovascular disease 31 (11)† 123 (5) 116 (25)† 138 (47)† Macroalbuminuria 2 (3)† 210 (8) 338 (73)† N/A Microalbuminuria 2…”
MethodIntensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052187 · Cited by 5,138
Goodpasture syndrome during the course of a Schönlein-Henoch purpura
Carreras, L., Poveda, R., Bas, J., Mestre, M., Rama, I., & Carrera, M. (2002) · American Journal of Kidney Diseases · doi:10.1053/ajkd.2002.32799 · Cited by 1,474
Albuminuria reflects widespread vascular damage: The Steno hypothesis
Deckert, T., Feldt-Rasmussen, B., Borch-Johnsen, K., Jensen, T., & Kofoed-Enevoldsen, A. (1989) · Diabetologia · doi:10.1007/bf00285287 · Cited by 1,400
Doqi, K. (2002) · American Journal of Kidney Diseases · Cited by 1,285
Global guideline for type 2 diabetes
(2014) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2012.10.001 · Cited by 1,064
Conditioning Diagnostics: Collinearity and Weak Data in Regression
Goldstein, R. (1993) · Technometrics · doi:10.1080/00401706.1993.10484997 · Cited by 911
(2004) · doi:10.1177/0049124103262065 · Cited by 906
Cited by
Items 601–651 of 651
UTILIZAÇÃO DE FITOTERÁPICOS EM PEDIATRIA: REVISÃO SISTEMÁTICA
Mamede, L. B., de Carvalho, G. B., & Terena, S. M. L. (2022) · Congresso Médico Acadêmico da Universidade Nove de Julho · doi:10.5585/comamedvg.2022.7
ACHADOS INCIDENTAIS EM TOMOGRAFIA COMPUTADORIZADA DO TÓRAX: UMA REVISÃO SISTEMÁTICA DE LITERATURA
Carneiro, L. G., Vêncio, I. M., Magalhães, A. F., & Meireles, D. P. (2022) · Congresso Médico Acadêmico da Universidade Nove de Julho · doi:10.5585/comamedvg.2022.4
O IMPACTO DA VACINA CONTRA O COVID-19 NO CICLO MENSTRUAL DE MULHERES: UMA REVISÃO NARRATIVA
Moujally, S. N., & Feliciano, R. D. S. (2022) · Congresso Médico Acadêmico da Universidade Nove de Julho · doi:10.5585/comamedvg.2022.3
TERAPIA DE FOTOBIOMODULAÇÃO EM BIOMATERIAL CARBONOSO E NANOPRATA NO MANEJO DE LESÕES ÓSSEAS
de Lima, J. G. C., Rodrigues, A. F., & Marcos, R. L. (2022) · Congresso Médico Acadêmico da Universidade Nove de Julho · doi:10.5585/comamedvg.2022.10
A UTILIZAÇÃO DA TOXINA BOTULÍNICA COMO ALTERNATIVA NO TRATAMENTO DA PARALISIA DE BELL
Almeida, G. D. S., Gonçalves, L. A., & Marques, E. R. M. D. C. (2022) · Congresso Médico Acadêmico da Universidade Nove de Julho · doi:10.5585/comamedvg.2022.25
INFLUÊNCIA DA DISBIOSE INTESTINAL SOBRE A DIABETES MELLITUS TIPO 2: ANÁLISE NARRATIVA
dos Santos, P. A. V., Vila, W. D. S., Franco, H. G. M., Souza, G. M., da Silva, V. L. L., & Viana, M. D. M. (2022) · Congresso Médico Acadêmico da Universidade Nove de Julho · doi:10.5585/comamedvg.2022.28
da Cunha, M. G. A. P., de Almeida, B. C., dos Anjos, L. G., Baracat, E. C., & Carvalho, K. C. (2022) · Congresso Médico Acadêmico da Universidade Nove de Julho · doi:10.5585/comamedvg.2022.2
TERAPIA ASSISTIDA POR ANIMAIS NO TRATAMENTO DE PACIENTES ONCOLÓGICOS: UMA REVISÃO DE LITERATURA
de Sá, M. M., do Nascimento, D. C. M., Valério, M. E. S., Amorim, G. S., Kobayashi, B. G., & Cardenes, K. M. V. D. H. (2022) · Congresso Médico Acadêmico da Universidade Nove de Julho · doi:10.5585/comamedvg.2022.24
Samak, M. (2023) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-9776 · Cited by 1
Pathomechanismen der chronischen Nierenschädigung bei Diabetes und anderen Begleiterkrankungen
Ganz, M. J., Bose, K., Herzog, C., Bender, S. T., Mertens, P. R., & Scurt, F. G. (2023) · Die Diabetologie · doi:10.1007/s11428-023-01020-9
Dart, A. B. (2023) · Springer eBooks · doi:10.1007/978-3-031-11665-0_32
Lipoproteins and Diabetic Kidney Disease
Sigfrids, F. J., Elonen, N., & Groop, P. (2023) · Contemporary diabetes · doi:10.1007/978-3-031-26681-2_15
Self-citationDong, Z., Cao, Z., Geng, Y., Zhang, Y., Wu, Y., Wang, Y., Zhang, C., Liu, B., Liu, Y., & Liu, W. J. (2023) · Research Square · doi:10.21203/rs.3.rs-2989601/v1
Кравчун, П. П., Дунаєва, І., Chernyavska, I. V., Oleinikova, S. P., & Kryvoshapka, O. V. (2023) · INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine) · doi:10.22141/2224-0721.19.6.2023.1316
Association of Hemoglobin Variability with Mortality in Dialysis Patients in Tertiary Hospital Nepal
Kandel, G., Sedhain, K., Thakur, P., Sapkota, P., & Sapkota, K. (2023) · Journal of National Heart and Lung Society Nepal · doi:10.3126/jnhls.v2i2.60357
Prevention and management of chronic kidney disease in diabetes
Barlovič, D. P., & Groop, P. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-88426-6.00004-x
Self-citationDeveloping Strategies to Improve Diabetes Management in College-Going Young Adults
(2024) · Frontiers research topics · doi:10.3389/978-2-8325-4815-8
Rouland, A. (2024) · theses.fr (ABES) · doi:10.70675/6af70b1eze632z469ez88c8zdb045a5e78c6
Choudhary, P., Rani, M., & Sengar, G. S. (2025) · Cureus · doi:10.7759/cureus.82202 · Cited by 2
What's new in the management of diabetic kidney disease
Zac‐Varghese, S. (2025) · British Journal of Diabetes · doi:10.15277/bjd.2025.479
Minhas, M. Q. (2025) · Journal of Student Research · doi:10.47611/jsrhs.v14i1.8495
Chronic Kidney Disease and Risk Management
(2025) · American Diabetes Association eBooks · doi:10.2337/9781580408462-ch18
Renal manifestations and diabetes mellitus: the missing link
Akpalu, J., Boima, V., & Abobi-Kanbigs, D. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-33090-2.00009-6
Maladie rénale chronique diabétique
Gosset, C., Rigalleau, V., Esnault, V. L. M., & Foussard, N. (2025) · EMC - Endocrinologie - Nutrition · doi:10.1016/s1155-1941(24)46692-4 · Cited by 1
Survival of patients with type 1 diabetes on renal replacement therapy
Helve, J. (2014) · Helda - University of Helsinki Institutional Repository · Cited by 1
Camoin, M., Velho, G., Saulnier, P.-J., Potier, L., Abouleka, Y., Carpentier, C., Dubois, S. G., Larroumet, A., Rigalleau, V., Gand, E., et al. (2022) · Figshare · doi:10.6084/m9.figshare.19736409
Parente, E. B., Harjutsalo, V., Forsblom, C. M., & Groop, P.-H. (2021) · Figshare · doi:10.6084/m9.figshare.15064684
Self-citationCamoin, M., Velho, G., Saulnier, P.-J., Potier, L., Abouleka, Y., Carpentier, C., Dubois, S. G., Larroumet, A., Rigalleau, V., Gand, E., et al. (2022) · Figshare · doi:10.6084/m9.figshare.19736406
Nugnes, M. (2024) · AMS Dottorato Institutional Doctoral Theses Repository (University of Bologna) · doi:10.48676/unibo/amsdottorato/11375
Camoin, M., Velho, G., Saulnier, P.-J., Potier, L., Abouleka, Y., Carpentier, C., Dubois, S. G., Larroumet, A., Rigalleau, V., Gand, E., et al. (2022) · Figshare · doi:10.6084/m9.figshare.19736400
Camoin, M., Velho, G., Saulnier, P.-J., Potier, L., Abouleka, Y., Carpentier, C., Dubois, S. G., Larroumet, A., Rigalleau, V., Gand, E., et al. (2022) · Figshare · doi:10.6084/m9.figshare.19736403
Parente, E. B., Harjutsalo, V., Forsblom, C. M., & Groop, P.-H. (2021) · Figshare · doi:10.6084/m9.figshare.15064687
Self-citationMartynov, S. A., Severina, A. S., Larina, I. M., Шамхаловна, Ш. М., В., А. С., Пинчук, А. В., & В., Ш. М. (2020) · Problems of Endocrinology
Combination therapy for kidney protection in type 1 diabetes mellitus: quo vadis?
Popovic, D. S., Patoulias, D., & Koufakis, T. (2026) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2026.113167
Man, Z., Zhang, S., Hu, G., Zhang, T., Mu, J., & Liao, Y. (2026) · Scientific Reports · doi:10.1038/s41598-026-39217-9
Jan, Y., Danyal, M., Hasan, S., & Khan, N. (2026) · Indus journal of bioscience research. · doi:10.70749/ijbr.v4i2.2933
Harjutsalo, V., Thorn, L. M., Sandholm, N., Groop, P., & FinnDiane Study Group* (2026) · Diabetes Care · doi:10.2337/dc25-2987
Self-citationRahbani, R., Taghavi, F., Abbasnezhad, M., Maleki, M., Liaghat, L., & Ghazipoor, H. (2026) · Galen Medical Journal · doi:10.31661/gmj.v15i.4090
“CKD amplifies these effects through pro - teinuria and reduced eGFR, correlating with higher cardiovascular events [20,21].”
Étude des déterminants génétiques et environnementaux des complications du diabète de type 2
Saulnier, P. (2012) · theses.fr (ABES) · doi:10.70675/14b55d61zd679z4afdzba10z373db62950dc · Cited by 1
Kiernan, E. A., & de Boer, I. H. (2026) · Diabetes Obesity and Cardiometabolic CARE · doi:10.2337/doci25-0009
Salidroside Regulates DN Podocyte Injury Through the LncRNA ZEB1-AS1/miR-21-5p/PDCD4 Axis
Li, W., & Gui, L. (2026) · Biochemical Genetics · doi:10.1007/s10528-026-11370-w
“The persistent DN hyperglycemic environment and progressive renal dysfunction lead to end-stage renal disease and some cardiovascular diseases (Afkarian et al. 2013, Groop et al. 2009).”
Prognosis of Type 1 Diabetes in Finland and its Determinants
Keisala, E. (2026) · Tampere University Institutional Repository (Tampere University)
The Role of the Klotho KL1 Domain in CKD-Associated Cardiac Fibrosis
Halim, A. (2026) · IUScholarWorks (Indiana University) · doi:10.7912/5zf3-yr46 · Cited by 1
Ylinen, A., Mutter, S., Hägg-Holmberg, S., Satuli-Autere, S., Harjutsalo, V., Groop, P., Thorn, L. M., & the FinnDiane Study Group (2026) · Journal of Diabetes · doi:10.1111/1753-0407.70249
“This finding was expected based on previous research [32–34].”
Self-citationSarvestani, F. S., Yaghobi, R., Maharlooei, M. K., Golshan, M., & Karimi, M. H. (2026) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.70215
“Patients continue to experience significant glycaemic fluctuations, recurrent episodes of hypo‐ and hyperglycemia, and a markedly increased risk of long‐term complications, including cardiovascular disease and chronic kidney disease [9–12].”
Baltu, D., & Cetin, Y. K. (2026) · Pediatric Nephrology · doi:10.1007/s00467-026-07524-y
Nicklén, J., Satuli-Autere, S., Rimpeläinen, K., Dufva, A., Ylinen, A., Franzen, E. M. C., Eriksson, M. I., Sigfrids, F. J., Öhman, H., & Thorn, L. M. (2026) · BMJ Open · doi:10.1136/bmjopen-2026-122380
Self-citationType 1 diabetes and cardiovascular medicine
Jenkins, A. J., Huang, M., Hemphill, M., Chen, D., Ha, J. T., Sata, Y., Sindone, A. P., Gnanenthiran, S. R., & Lan, N. S. R. (2026) · Cardiovascular Diabetology – Endocrinology Reports · doi:10.1186/s40842-026-00338-9
“CVD remains the leading cause of death in people with T1D and CKD, with risk increasing progressively with worsening eGFR and albuminuria [93, 94].”
Diabetes Mellitus: Review of the Common, Rare, and Uncommon (Conceptual and Metaphorical) Types
Pliszka, M., & Szablewski, L. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27219611
SGLT2 Inhibitors in Type 1 Diabetes Mellitus: The Kidney and Heart Perspective
Barlovic, D. P., & Groop, P.-H. (2026) · Handbook of experimental pharmacology · doi:10.1007/164_2026_865
Self-citation
Metadata
- Authors
- Groop, P.-H., Thomas, M. C., Moran, J. L., Wadèn, J., Thorn, L. M., Mäkinen, V.-P., Rosengård-Bärlund, M., Saraheimo, M., Hietala, K., Heikkilä, O., & Forsblom, C.
- Affiliations
- Helsinki University Hospital (FI)
- Baker Heart and Diabetes Institute (AU)
- Department of Intensive Care Medicine, The Queen Elizabeth Hospital, Woodville, South Australia, Australia;
- Folkhälsan Institute of Genetics, Folkhälsan Research Center, Biomedicum Helsinki, Helsinki, Finland;
- Corresponding author
- Groop, Per-Henrik
- ORCID
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2009-04-28
- Volume
- 58
- Issue
- 7
- Pages
- 1651-1658
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- PMC
- PMC2699848
- OpenAlex
- W2101457616
- Semantic Scholar
- 8c94474962d440b785728afdfb3a4ed830eedf9d
- Cited by
- 638
- References
- 49
- Citations by year
- 2026: 14 · 2025: 29 · 2024: 30 · 2023: 38 · 2022: 59 · 2021: 43 · 2020: 40 · 2019: 48 · 2018: 55 · 2017: 43 · 2016: 40 · 2015: 41 · 2014: 54 · 2013: 40 · 2012: 23
- FWCI
- 14.75
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion, cc-by-nc-nd)
- Minerva Access (University of Melbourne) (submittedVersion, cc-by-nc-nd)
- Funders
- Wilhelm och Else Stockmanns Stiftelse
- European Commission
- Signe ja Ane Gyllenbergin Säätiö
- Waldemar von Frenckells Stiftelse
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- type 1 diabetes, chronic kidney disease, all-cause mortality, diabetic nephropathy, albuminuria, microalbuminuria, macroalbuminuria, end-stage renal disease, glomerular filtration rate, hyperfiltration, standardized mortality ratio
- MeSH terms
- Adolescent, Adult, Cause of Death, Diabetes Mellitus, Type 1, Diabetic Nephropathies, Female, Finland, Follow-Up Studies, Glomerular Filtration Rate, Humans, Insulin, Male, Middle Aged, Severity of Illness Index, Cohort Studies, Age of Onset, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.